Polynovo Share Price and Company Fundamentals
Last traded: Today at 3:51 AM
Polynovo Limited develops medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing Syntrel hernia devices for hernia repair; breast devices in partnership with Establishment Labs; NovoSorb dermal beta cell implant in collaboration with BetaCell Technologies Pty Ltd; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited was incorporated in 1998 and is based in Port Melbourne, Australia.
|Primary activities||PolyNovo develops and commercialises innovative medical devices using its NovoSorb technology in the treatment of burns, surgical wounds and Negative Pressure Wound Therapy.|
|Industry / Sector||Biotechnology / Healthcare|
|Full time employees||91|
|Mailing address||320 Lorimer Street Unit 2 Port Melbourne VIC 3207 Australia|
|Phone / Fax||61 3 8681 4050 / 61 3 8681 4099|
|Share registry||COMPUTERSHARE INVESTOR SERVICES PTY LIMITED|
Polynovo does not pay dividends.
As of May 2021, following are the company executives and directors listed on Polynovo.
|Mr. Paul Brennan||CEO, MD & Director||500.27k|
|Mr. Jan-Marcel Gielen C.A.||CFO & Company Sec.||227.38k|
|Dr. Anthony Kaye||Chief Operating Officer|
|Ms. Katherine Napier||Marketing & Distributor Mang.|
|Ms. Monica Benyk||HR Mang.|
|Dr. Tim Moore||Principal Scientist|
|Mr. Edward Graubart||Sr. VP of North America|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Polynovo is 1.72B and its enterprise value is 1.97B. The enterprise value to revenue ratio of PNV is 79.85.
The PNV's stocks Beta value is 1.18 making it 18% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Polynovo (PNV)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Pro Medicus (PME)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Polynovo (ASX:PNV) Frequently Asked Questions
1. What is Polynovo's Stock Symbol?
Polynovo trades on ASX under the ticker symbol "PNV".
2. What is Polynovo's stock price today?
One share of PNV stock can currently be purchased for approximately $2.6.
3. How can I contact Polynovo?
Polynovo's mailing address is 320 Lorimer Street Unit 2 Port Melbourne VIC 3207 Australia. The company can be reached via phone at 61 3 8681 4050.
4. What is Polynovo's official website?
The official website of Polynovo is http://www.polynovo.com.au.
5. Which share registry manages Polynovo's stock?
Polynovo's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.